MedPath

APOTEX CORP.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.apotex.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

161

FDA:161

Drug Approvals

Rivaroxaban

Approval Date
Jul 7, 2025
FDA

Bupropion Hydrochloride

Approval Date
Jun 19, 2025
FDA

Nilotinib

Approval Date
Apr 22, 2025
FDA

Bendamustine Hydrochloride

Approval Date
Apr 2, 2024
FDA

BORTEZOMIB

Approval Date
Mar 20, 2024
FDA

Lacosamide

Approval Date
Mar 16, 2024
FDA

Lacosamide Oral Solution

Approval Date
Mar 13, 2024
FDA

Dexamethasone

Approval Date
Mar 8, 2024
FDA

ICATIBANT

Approval Date
Feb 29, 2024
FDA

Pazopanib

Approval Date
Feb 28, 2024
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 17
  • Next

Clinical Trials

No trials found

News

Apotex Launches First Generic Nilotinib in US with 180-Day Market Exclusivity

Apotex Corp. announced the launch of nilotinib capsules, the first generic version of Tasigna® in the United States, with 180 days of market exclusivity.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy